Antibody Fragments Market Report 2026

The antibody fragments market size has grown strongly in recent years. It will grow from $11.26 billion in 2025 to $12.31 billion in 2026 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to advancement of monoclonal antibody technologies, clinical success of antibody-derived therapies, growth in cancer biologics research, expansion of diagnostic antibody usage, increased investment in biologics R&D.

The antibody fragments market size is expected to see strong growth in the next few years. It will grow to $17.56 billion in 2030 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to growth in targeted cancer therapies, expansion of antibody fragment pipelines, increasing demand for precision biologics, rising use in companion diagnostics, innovation in recombinant antibody engineering. Major trends in the forecast period include rising adoption of fragment-based biologics, increasing use in oncology and targeted therapies, growing demand for high-penetration antibody formats, expansion of diagnostic applications, increased focus on reduced immunogenicity treatments.

The rising incidence of target diseases is anticipated to boost the antibody fragments market in the future. Target diseases refer to particular illnesses or health conditions that medications, treatments, or medical studies seek to prevent, control, or treat. Key target diseases encompass cancer, infectious diseases, and bacterial infections. This upward trend in target diseases stems primarily from poor lifestyle choices and pollution, which compromise the body's immune system and contribute to chronic conditions. Antibody fragments offer precise, targeted, and adaptable solutions for addressing diverse diseases, typically with fewer side effects than conventional treatments. Their capacity for customization and engineering toward specific targets positions them as a vital asset in contemporary medicine. For example, in January 2025, a report from the American Cancer Society - a U.S.-based nonprofit - forecasted 2,041,910 new cancer cases and 618,120 cancer deaths in the United States for 2025, up from 2,001,140 new cases and 611,720 deaths in 2024. Thus, the growing prevalence of target diseases fuels expansion in the antibody fragments market.

Major companies in the antibody fragments market are prioritizing clinical trials to create innovative products, like human VH antibody fragments, which boost the effectiveness of targeted therapies and lower immunogenicity for treating cancers, autoimmune conditions, and infectious diseases. A human VH antibody fragment consists of the variable domain from the heavy chain of a human antibody, able to bind antigens on its own. It functions as the core antigen-binding part in antibody fragments, commonly applied solo or combined with other elements to produce compact, stable, high-affinity antibodies for therapy or diagnostics. For example, in May 2024, Zai Lab Limited, a pharmaceutical firm based in China, launched a worldwide Phase 2 clinical trial assessing the efficacy and safety of ZL-1102. ZL-1102 represents a new human VH antibody fragment (Humabody) targeting IL-17, developed as a topical treatment for mild-to-moderate chronic plaque psoriasis to enhance precision while minimizing systemic side effects and immunogenic reactions.

In September 2024, Valerio Therapeutics S.A., a France-based clinical-stage biotechnology company, acquired Emglev Therapeutics for an undisclosed sum. Through this acquisition, Valerio Therapeutics bolsters its antibody discovery platform by incorporating Emglev Therapeutics’ synthetic single-domain antibody (sdAb) technology to broaden therapeutic possibilities. Emglev Therapeutics is a France-based biotechnology company focused on developing synthetic single-domain antibodies (sdAb).

Major companies operating in the antibody fragments market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Sanofi S.A., AstraZeneca PLC, Novartis AG, GSK plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Biogen Inc., UCB S.A., Bio-Rad Laboratories Inc., Genmab A/S, WuXi Biologics Co. Ltd., Abcam plc, MacroGenics Inc., Harbour BioMed, Creative Biolabs Inc.

North America was the largest region in the antibody fragments market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antibody fragments market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the antibody fragments market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the antibody fragments market by increasing the cost of imported active pharmaceutical ingredients, biologic intermediates, and specialized manufacturing inputs used in antibody engineering. These impacts have been most pronounced in oncology and diagnostic segments, particularly in north america and europe where biologics supply chains are globally integrated. Asia-pacific manufacturers have faced cost pressures and sourcing delays. However, tariffs have encouraged localized biologics manufacturing and regional production capabilities, supporting supply continuity.

The antibody fragments market research report is one of a series of new reports that provides antibody fragments market statistics, including antibody fragments industry global market size, regional shares, competitors with a antibody fragments market share, detailed antibody fragments market segments, market trends and opportunities, and any further data you may need to thrive in the antibody fragments industry. This antibody fragments market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Antibody fragments are smaller segments of antibodies that maintain their capacity to bind specific antigens. Derived from complete antibodies, they are engineered for greater stability, improved tissue penetration, and fewer immune responses, rendering them valuable in therapeutic and diagnostic uses.

The primary types of antibody fragments consist of F(ab) fragments, F(ab’)₂ fragments, single-chain variable fragments (scFvs), single-domain antibody fragments (sdAbs), and additional variants. F(ab) fragments feature a single antigen-binding site and exclude the Fc region to minimize immune responses, making them ideal for diagnostic and therapeutic uses. Depending on specificity, antibody fragments fall into categories of monoclonal or polyclonal antibodies. Delivery options include intravenous (IV), subcutaneous (SC), oral, or transdermal routes, supporting applications like cancer therapy, immunodeficiencies, and various medical conditions. Major end users encompass pharmaceutical companies, biotechnology firms, research institutions, diagnostic labs, and contract research organizations (CROs).

The antibody fragments market consists of revenues earned by entities by providing services such as pharmacokinetics and toxicology testing, clinical and regulatory support services, custom conjugation services, and antibody fragment production and expression services. The market value includes the value of related goods sold by the service provider or included within the service offering. The antibody fragments market also includes sales of diabodies and tribodies, nanobodies, antibody-based therapeutics, and diagnostic agents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.